

**Question for written answer E-001193/2018  
to the Commission**

Rule 130

**György Hölvényi (PPE)**

Subject: Research on thrombosis and haemostasis under Horizon 2020 and Framework Programme 9 (FP9)

One in four people worldwide die of conditions caused by blood clots, also known by the clinical term 'thrombosis', which is the underlying cause of cardiovascular disorders such as heart attack, thromboembolic stroke and venous thromboembolism (VTE). As the risk of VTE increases with age, further research into thrombosis and haemostasis is vital in order to prepare Member States for the challenge of ageing populations, increased demand for healthcare services and the costs of effectively meeting this demand.

VTE is estimated to cost EU health systems EUR 1.5-2.2 billion per year in direct costs, while indirect costs such as disability and productive life years lost are estimated to be as high as EUR 13.2 billion per year. Supporting and stimulating research on thrombosis and haemostasis in the upcoming FP9 is therefore crucial.

Can the Commission clarify how much funding it has allocated so far to thrombosis and haemostasis under Horizon 2020?

Does it agree that thrombosis and haemostasis should be a priority in the upcoming FP9 and if so, how does it plan to stimulate research into thrombosis and haemostasis?